Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting
Tóm tắt
Despite being first described 45 years ago, the existence of a distinct diabetic cardiomyopathy remains controversial. Nonetheless, it is widely accepted that the diabetic heart undergoes characteristic structural and functional changes in the absence of ischaemia and hypertension, which are independently linked to heart failure progression and are likely to underlie enhanced susceptibility to stress. A prominent feature is marked collagen accumulation linked with inflammation and extensive extracellular matrix changes, which appears to be the main factor underlying cardiac stiffness and subclinical diastolic dysfunction, estimated to occur in as many as 75% of optimally controlled diabetics. Whether this characteristic remodelling phenotype is primarily driven by microvascular dysfunction or alterations in cardiomyocyte metabolism remains unclear. Although hyperglycaemia regulates multiple pathways in the diabetic heart, increased reactive oxygen species (ROS) generation is thought to represent a central mechanism underlying associated adverse remodelling. Indeed, experimental and clinical diabetes are linked with oxidative stress which plays a key role in cardiomyopathy, while key processes underlying diabetic cardiac remodelling, such as inflammation, angiogenesis, cardiomyocyte hypertrophy and apoptosis, fibrosis and contractile dysfunction, are redox sensitive. This review will explore the relative contributions of the major ROS sources (dysfunctional nitric oxide synthase, mitochondria, xanthine oxidase, nicotinamide adenine dinucleotide phosphate oxidases) in the diabetic heart and the potential for therapeutic targeting of ROS signalling using novel pharmacological and non-pharmacological approaches to modify specific aspects of the remodelling phenotype in order to prevent and/or delay heart failure development and progression.
Từ khóa
Tài liệu tham khảo
Ponikowski, 2016, ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur Heart J, 2016, 2129, 10.1093/eurheartj/ehw128
Scheen, 2017, GLP-1 receptor agonists and heart failure in diabetes, Diabetes Metab, 432S, 2S13, 10.1016/S1262-3636(17)30068-X
Heusch, 2014, Cardiovascular remodelling in coronary artery disease and heart failure, The Lancet, 383, 1933, 10.1016/S0140-6736(14)60107-0
Kanamori, 2015, Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes, Autophagy, 11, 1146, 10.1080/15548627.2015.1051295
Kawata, 2015, Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus, Cardiovasc Diabetol, 14, 98, 10.1186/s12933-015-0263-7
Battelli, 1842, Pathophysiology of circulating xanthine oxidoreductase: New emerging roles for a multi-tasking enzyme, Biochim Biophys Acta, 2014, 1502
Zheng, 2015, Exogenous Hydrogen Sulfide Attenuates Cardiac Fibrosis Through Reactive Oxygen Species Signal Pathways in Experimental Diabetes Mellitus Models, Cell Physiol Biochem, 36, 917, 10.1159/000430266
Kietzmann, 2017, The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system, Br J Pharmacol, 174, 1533, 10.1111/bph.13792
Kornicka, 2017, The effects of the DNA methyltranfserases inhibitor 5-Azacitidine on ageing, oxidative stress and DNA methylation of adipose derived stem cells, J Cell Mol Med, 21, 387, 10.1111/jcmm.12972